ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
3B Pharmaceuticals Announces Option and Asset Purchase Agreement with Novartis for PSMA Radioligand Therapy Program
RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver
3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology
3B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6th Theranostic World Congress
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
3B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis